论文部分内容阅读
目的:观察心脑欣胶囊联合全天麻胶囊治疗偏头痛的临床疗效,及其对患者脑血管血流动力学指标的影响。方法:选取148例偏头痛患者为研究对象,按照患者入院顺序编号,奇数号设为对照组,偶数号设为观察组,每组74例。对照组给予盐酸氟桂利嗪胶囊治疗,观察组给予心脑欣胶囊联合全天麻胶囊治疗。治疗后观察2组临床疗效,以及治疗前后脑血管[大脑前动脉(ACA)、大脑后动脉(PCA)、大脑中动脉(MCA)、椎动脉(VA)及基底动脉(BA)]的平均血流速度和头痛次数、头痛指数的变化。结果:总有效率观察组为95.95%,高于对照组的75.68%,差异有统计学意义(P<0.01)。治疗前,2组ACA、PCA、MCA、VA、BA的平均血流速度比较,差异均无统计学意义(P>0.05)。治疗后,2组各项脑血管平均血流速度值均较治疗前降低(P<0.05),观察组的各项脑血管平均血流速度值均低于对照组(P<0.05)。治疗前,2组头痛次数和头痛指数比较,差异均无统计学意义(P>0.05)。治疗后,2组头痛次数和头痛指数均较治疗前降低(P<0.05),观察组的头痛次数和头痛指数的下降程度均大于对照组(P<0.05)。结论:心脑欣胶囊联合全天麻胶囊治疗偏头痛临床疗效显著,可有效降低ACA、PCA、MCA、VA、BA的平均血流速度,改善偏头痛症状。
Objective: To observe the clinical efficacy of Xinnaoxin capsule combined with Quantiandi capsule on migraine and its effect on cerebral vascular hemodynamics in patients. Methods: A total of 148 cases of migraine were enrolled in this study. The patients were admitted to hospital according to the order they were admitted. Odd numbers were set as the control group and the even numbers were assigned as the observation group with 74 cases in each group. The control group was treated with Flunarizine Hydrochloride Capsule. The observation group was treated with Xinnaoxin Capsule and Tianma Capsule. After treatment, the clinical curative effect of the two groups were observed, and the average blood levels of cerebral blood vessels (ACA, PCA, MCA, VA, and BA) before and after treatment Flow rate and the number of headaches, headache index changes. Results: The total effective rate in observation group was 95.95%, which was higher than that in control group (75.68%), the difference was statistically significant (P <0.01). Before treatment, the average blood flow velocity of ACA, PCA, MCA, VA and BA in two groups had no significant difference (P> 0.05). After treatment, the average cerebrovascular mean velocity of blood flow in the two groups was significantly lower than that before treatment (P <0.05). The average cerebrovascular mean velocity was lower in the observation group than that in the control group (P <0.05). Before treatment, there were no significant differences in the number of headache and headache between the two groups (P> 0.05). After treatment, the number of headache and headache index in both groups were lower than those before treatment (P <0.05), and the headache and headache index decreased more in the observation group than in the control group (P <0.05). Conclusion: The clinical effect of Xinnaoxin capsule and Quantiandi capsule on migraine is significant, which can effectively reduce the average blood flow velocity of ACA, PCA, MCA, VA, BA and improve the migraine symptoms.